Literature DB >> 11049729

Update on Substance P (NK-1 receptor) antagonists in clinical trials for depression.

M S Kramer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11049729     DOI: 10.1054/npep.2000.0830

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


× No keyword cloud information.
  6 in total

1.  Characteristics of substance P transport across the blood-brain barrier.

Authors:  Arvind K Chappa; Kenneth L Audus; Susan M Lunte
Journal:  Pharm Res       Date:  2006-06-01       Impact factor: 4.200

Review 2.  Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation.

Authors:  Steven D Douglas; Susan E Leeman
Journal:  Ann N Y Acad Sci       Date:  2010-11-22       Impact factor: 5.691

3.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

Review 4.  Neuropeptide and sigma receptors as novel therapeutic targets for the pharmacotherapy of depression.

Authors:  Konstantinos A Paschos; Stavroula Veletza; Ekaterini Chatzaki
Journal:  CNS Drugs       Date:  2009-09       Impact factor: 5.749

Review 5.  Facilitating compound progression of antiretroviral agents via modeling and simulation.

Authors:  Jeffrey S Barrett
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-17       Impact factor: 4.147

6.  The role of substance P in depression: therapeutic implications.

Authors:  Markus J Schwarz; Manfred Ackenheil
Journal:  Dialogues Clin Neurosci       Date:  2002-03       Impact factor: 5.986

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.